Physician profile
Judyth Valera
NPI 1265609499
$3,143.02
in general payments reported to CMS, 2019-2025
33 companies · $510 in 2025
The $510 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $630 · 2022: $580 · 2023: $734 · 2024: $690 · 2025: $510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,934.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,933.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $805.22 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $290.42 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $244.96 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.19 | 2021-2024 | |
| Pfizer INC. | $202.08 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $151.50 | 2022-2024 | Quviviq |
| Glaxosmithkline, LLC. | $146.64 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $125.79 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Almatica Pharma LLC | $110.94 | 2021-2024 | Loreev Xr, Gralise, Sertraline Hcl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.62 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $79.77 | 2022-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $77.08 | 2024 | |
| Lundbeck LLC | $69.69 | 2024-2025 | Rexulti |
| Amgen INC. | $64.43 | 2022-2023 | Otezla, Repatha |
| Abbvie INC. | $56.47 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $49.14 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.17 | 2021-2025 | Xifaxan |
| Eisai INC. | $42.63 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $33.48 | 2024-2025 | Azmiro, Edarbi |
| Merck Sharp & Dohme LLC | $28.58 | 2022-2024 | Lagevrio |
| Abbott Laboratories | $24.00 | 2021 | |
| Dexcom, INC. | $16.53 | 2024 | Dexcom G6 Transmitter |
| Echosens North America, INC. | $15.91 | 2025 | Fibroscan |
| Amphastar Pharmaceuticals, INC. | $14.89 | 2024 | |
| Neurocrine Biosciences, INC. | $14.74 | 2023 | Ingrezza |
| Acerus Pharmaceuticals Corporation | $14.28 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $14.28 | 2023 | Nuedexta |
| Seqirus USA INC | $14.06 | 2022 | |
| Sanofi Pasteur INC. | $13.90 | 2023 | |
| Sanofi-Aventis U.S. LLC | $12.42 | 2021 | |
| Sun Pharmaceutical Industries INC. | $12.41 | 2021 | |
| Currax Pharmaceuticals LLC | $12.28 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judyth Valera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.